U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H56O11
Molecular Weight 676.8339
Optical Activity UNSPECIFIED
Defined Stereocenters 19 / 19
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACTEIN

SMILES

[H][C@]12C[C@@]3(C)[C@]4([H])CC[C@]5([H])[C@]6(C[C@@]46C[C@@H](OC(C)=O)[C@]3(C)[C@@]1([H])[C@H](C)C[C@]7(O[C@H](O)[C@@]8(C)O[C@@H]78)O2)CC[C@H](O[C@]9([H])OC[C@@H](O)[C@H](O)[C@H]9O)C5(C)C

InChI

InChIKey=NEWMWGLPJQHSSQ-PSDKAYTQSA-N
InChI=1S/C37H56O11/c1-17-12-37(29-34(7,47-29)30(42)48-37)46-20-13-32(5)22-9-8-21-31(3,4)23(45-28-27(41)26(40)19(39)15-43-28)10-11-35(21)16-36(22,35)14-24(44-18(2)38)33(32,6)25(17)20/h17,19-30,39-42H,8-16H2,1-7H3/t17-,19-,20+,21+,22+,23+,24-,25+,26+,27-,28+,29-,30+,32+,33-,34+,35-,36+,37-/m1/s1

HIDE SMILES / InChI

Description

Actein is tetracyclic triterpenoid compound isolated from the rhizome of Cimicifuga foetida L. In North America, the cimicifuga species had a long medicinal history, mainly used to treat diarrhea, sore throat, and rheumatism. Actein inhibits the activity of the Na,K-ATPase, which affects calcium metabolism. The primary target of actein may relate to calcium metabolism since this agent altered the expression of several genes related to calcium. Although actein was shown to exhibit other pathological functions, such as prevention of oxidative damage to osteoblast and regulation of lipid disorder, the major role of actein is played on its anticancer activity, particularly in breast cancer.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
11.2 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Mouse: 10-15 mg/kg for 28 days
Route of Administration: Oral
In Vitro Use Guide
MC3T3-E1 osteoblastic cells were pretreated with actein (0.01–1 uM) for 1 h and then exposed to 100 nM 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) for 48 h. Cell viability was again measured using the water-soluble tetrazolium (WST) assay. Actein-pretreated cells had increased viability compared to those treated with TCDD only, in a concentration-dependent manner. The TCDD-induced increased apoptosis was also restored to a level similar to that in the control group by pretreatment with 1 uM actein. Pretreatment with actein also prevented TCDD-induced autophagic activity in a concentration-dependent manner. Taking these findings together, pretreatment with actein protected MC3T3-E1 osteoblastic cells from TCDD-induced apoptosis